Bioasis Technologies Inc. BIOAF
0.00 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.0001 Day range 0.0001
0.0001 52-week range 0.0002
- YTD
- -50.00%
- 1 year
- -50.00%
- Market cap
- 7.94K
- YTD return
- -50.00%
- 1-year return
- -50.00%
- Volume
- 72.94K
- Avg volume
- 2.93K
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0002
1Y -0.0001 (-50.00%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 19, 2023 | Nov 1, 2022 | -0.01 | -0.01 | 0.00 | 0.00% |
| Oct 28, 2022 | Aug 1, 2022 | 0.00 | -0.01 | — | — |
News
Financial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF) 
Bioasis to Attend Upcoming Industry Conferences 
Bioasis Technologies Inc. Announces the Appointment of Shadow Lake Group as Business Development Advisor 
Bioasis Announces Allowance of Japanese Patent Application in Japan Relating to xB³™ Fusion Protein Comprising Iduronate-2-sulfatase 
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A 
Bioasis Technologies Inc. Announces Stock Option Grants, Jeffrey Sprouse Appointed Preclinical Program Manager 
Bioasis Technologies reports positive results from an efficacy study of its blood-brain barrier penetrant 
Bioasis Announces Positive Results From an Efficacy Study of xB3™-IL-1RA in a Model of Multiple Sclerosis 
Bioasis Technologies appoints former PricewaterhouseCoopers veteran Dave Jenkins as CFO 
Bioasis Announces the Appointment of Dave Jenkins as Chief Financial Officer
Your note
Sign in to keep a note on BIOAF — it syncs with the Stock Master app.